Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2022 | What is radiomics?

Dirk De Ruysscher • 20 May 2022
ESTRO 2022
General

Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands, and University of Leuven, Leuven, Belgium, explains what radiomics is and discusses its benefits and possible applications. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.

More from Dirk De Ruysscher

2:01
How could radiomics improve oncology care in the future?
Dirk De Ruysscher • 20 May 2022
3:11
Unmet needs in radiomics
Dirk De Ruysscher • 20 May 2022
7:22
Early updates from the CheckMate73L study: nivo + CCRT followed by nivo + ipi in NSCLC
Dirk De Ruysscher • 6 Oct 2021
6:46
Radiomics in oncology
Dirk De Ruysscher • 6 Oct 2021

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals